Big Pharma Tries Out New Class On The Diabetes Block: SGLT-2
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Could controlling type 2 diabetes be as simple as dumping excess sugar out of the body via the urine? Some Big Pharmas are betting on it, and with good Phase II results rolling in, enthusiasm is growing for a new mechanism of action that targets glucose in the kidneys instead of tinkering with insulin.